JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4123 KW 2449

Target: Aurora Kinases|FLT3|Bcr-Abl

Summary: Multikinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥16.6 mg/mL
B5846 Radotinib(IY-5511)

Target: PDGFR|Bcr-Abl

Summary: Bcr-Abl tyrosine kinase inhibitor

≥13.73 mg/mL
B1299 1-NM-PP1

Target: Cyclin-Dependent Kinases|Bcr-Abl|Src|Ca2 /calmodulin-dependent protein kinases (CaMKs)|c-Fyn

Summary: Pp60c-src inhibitor

insoluble in H2O; ≥16.55 mg/mL
B2171 Imatinib (STI571)

Target: PDGFR|c-Kit|Bcr-Abl

Summary: Protein-tyrosine kinase inhibitor

≥24.68 mg/mL
A8232 Nilotinib(AMN-107)
1 Citation

Target: Bcr-Abl

Summary: Bcr-Abl kinase inhibitor,selective

≥26.5 mg/mL
A2412 CP-724714

Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R

Summary: HER2 inhibitor,potent and selective

≥23.5 mg/mL
A5467 Ponatinib (AP24534)
1 Citation

Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src

Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor

≥53.3 mg/mL
A8604 GNF 5

Target: Bcr-Abl

Summary: Bcr-Abl inhibitor
A8812 PD173955

Target: Bcr-Abl|Src

Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,

≥22.15 mg/mL
B2172 PP121

Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|Hck

Summary: Dual inhibitor of tyrosine and phosphoinositide kinases